These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9805207)

  • 1. Is NADH effective in the treatment of Parkinson's disease?
    Swerdlow RH
    Drugs Aging; 1998 Oct; 13(4):263-8. PubMed ID: 9805207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
    Kuhn W; Müller T; Winkel R; Danielczik S; Gerstner A; Häcker R; Mattern C; Przuntek H
    J Neural Transm (Vienna); 1996; 103(10):1187-93. PubMed ID: 9013405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
    Birkmayer GJ; Birkmayer W
    Acta Neurol Scand Suppl; 1989; 126():183-7. PubMed ID: 2618590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy and tactic of modern Parkinson therapy.
    Birkmayer W; Birkmayer GJ
    Acta Neurol Scand Suppl; 1989; 126():63-6. PubMed ID: 2694735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.
    Birkmayer W; Birkmayer GJ; Vrecko K; Mlekusch W; Paletta B; Ott E
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):297-302. PubMed ID: 2597315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
    Demarin V; Podobnik SS; Storga-Tomic D; Kay G
    Drugs Exp Clin Res; 2004; 30(1):27-33. PubMed ID: 15134388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.
    Birkmayer JG; Vrecko C; Volc D; Birkmayer W
    Acta Neurol Scand Suppl; 1993; 146():32-5. PubMed ID: 8101414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
    Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of NADH on dopamine release in rat striatum.
    Pearl SM; Antion MD; Stanwood GD; Jaumotte JD; Kapatos G; Zigmond MJ
    Synapse; 2000 May; 36(2):95-101. PubMed ID: 10767056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.